Performance of laboratories in antimicrobial susceptibility testing of MB-16-02
| Antibiotics | MIC | Antibiotics | Disk | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | I | R | IND | S | I | R | IND | ||
| CLSI group A | |||||||||
| Ampicillin/Sulbactam | 16 | 172 | Ampicillin/Sulbactam | 3 | 4 | 8 | |||
| Ceftazidime | 211 | Ceftazidime | 21 | ||||||
| Ciprofloxacin | 208 | Ciprofloxacin | 24 | ||||||
| Levofloxacin | 50 | Levofloxacin | 8 | ||||||
| Gentamicin | 214 | Gentamicin | 23 | ||||||
| Tobramycin | 38 | Tobramycin | 15 | ||||||
| Imipenem | 204 | Imipenem | 24 | ||||||
| Meropenem | 174 | Meropenem | 14 | ||||||
| Other CLSI groups | |||||||||
| Amikacin | 110 | Amikacin | 22 | ||||||
| Cefepime | 166 | Cefepime | 8 | ||||||
| Cefotaxime | 117 | Cefotaxime | 14 | ||||||
| Ceftriaxone | 1 | Ceftriaxone | 8 | ||||||
| Colistin | 30 | Colistin | 1 | ||||||
| Minocycline | 94 | 5 | 1 | Minocycline | 4 | ||||
| Piperacillin | 36 | Piperacillin | 4 | ||||||
| Piperacillin/Tazobactam | 128 | Piperacillin/Tazobactam | 6 | ||||||
| Ticarcillin/Clavulanic acid | 12 | Ticarcillin/Clavulanic acid | 11 | ||||||
| Tigecycline | 6 | Tigecycline | 5 | ||||||
| Trimethoprim/Sulfamethoxa | 2 | 129 | Trimethoprim/Sulfamethoxa | 15 | |||||
| Unacceptable | |||||||||
| Amoxicillin/Clavulanic acid | 1 | Amoxicillin/Clavulanic acid | 2 | ||||||
| Ampicillin | 1 | Ampicillin | 5 | ||||||
| Aztreonam | 14 | Aztreonam | 2 | 6 | |||||
| Clinafloxacin | 3 | Carbenicillin | 1 | ||||||
| Tetracycline | 2 | Cefamandole | 1 | ||||||
| Cefazolin | 2 | ||||||||
| Cefoperazone | 3 | ||||||||
| Cefoperazone/Sulbactam | 1 | ||||||||
| Cefotetan | 1 | ||||||||
| Ceftizoxime | 1 | ||||||||
| Cephalothin | 3 | ||||||||
| Ofloxacin | 1 | ||||||||
| Penicillin G | 2 | ||||||||
| Rifampin | 1 | ||||||||
| Tigecycline | 1 | ||||||||
Abbreviations: MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistance; IND, indeterminate; CLSI, Clinical and Laboratory Standards Institute.